These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28209656)

  • 1. Changes in allele frequencies of
    Nooruddin Z; Miltgen N; Wei Q; Schowinsky J; Pan Z; Tobin J; Purev E; Gutman JA; Robinson W; Pollyea DA
    Haematologica; 2017 May; 102(5):e207-e209. PubMed ID: 28209656
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent
    Gunawan AS; McLornan DP; Wilkins B; Waghorn K; Hoade Y; Cross NCP; Harrison CN
    Haematologica; 2017 Jun; 102(6):e238-e240. PubMed ID: 28302714
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.
    Lasho TL; Mims A; Elliott MA; Finke C; Pardanani A; Tefferi A
    Leukemia; 2014 Jun; 28(6):1363-5. PubMed ID: 24445868
    [No Abstract]   [Full Text] [Related]  

  • 4. Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy.
    Stoner RC; Press RD; Maxson JE; Tyner JW; Dao KT
    Leukemia; 2020 Jun; 34(6):1684-1688. PubMed ID: 31844143
    [No Abstract]   [Full Text] [Related]  

  • 5. Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation.
    Hinze A; Rinke J; Hochhaus A; Ernst T
    Ann Hematol; 2021 Feb; 100(2):581-584. PubMed ID: 32577845
    [No Abstract]   [Full Text] [Related]  

  • 6. Genomics of chronic neutrophilic leukemia.
    Maxson JE; Tyner JW
    Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
    Qian Y; Chen Y; Li X
    Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.
    Ikeda Y; Yamanouchi J; Takenaka K
    Ann Hematol; 2021 Oct; 100(10):2639-2641. PubMed ID: 32676732
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.
    Stahl M; Xu ML; Steensma DP; Rampal R; Much M; Zeidan AM
    Ann Hematol; 2016 Jun; 95(7):1197-200. PubMed ID: 27068405
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
    Ouyang Y; Qiao C; Chen Y; Zhang SJ
    Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Response of Chronic Neutrophilic Leukemia With CSF3R T618I, SETBP1, and ASXL1 Mutations After Decitabine Therapy.
    Cao S; Tao Q; Wang J; Zhang Q; Dong Y
    Am J Ther; 2024 Sep-Oct 01; 31(5):e550-e552. PubMed ID: 39292831
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
    Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
    J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
    Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
    Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia.
    Cui Y; Li B; Gale RP; Jiang Q; Xu Z; Qin T; Zhang P; Zhang Y; Xiao Z
    J Hematol Oncol; 2014 Oct; 7():77. PubMed ID: 25316523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
    Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
    Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.
    Ammatuna E; Eefting M; van Lom K; Kavelaars FG; Valk PJ; Touw IP
    Ann Hematol; 2015 May; 94(5):879-80. PubMed ID: 25491280
    [No Abstract]   [Full Text] [Related]  

  • 17. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.
    Pardanani A; Lasho TL; Laborde RR; Elliott M; Hanson CA; Knudson RA; Ketterling RP; Maxson JE; Tyner JW; Tefferi A
    Leukemia; 2013 Sep; 27(9):1870-3. PubMed ID: 23604229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.
    Carratt SA; Kong GL; Curtiss BM; Schonrock Z; Maloney L; Maniaci BN; Blaylock HZ; Baris A; Druker BJ; Braun TP; Maxson JE
    Blood; 2022 Aug; 140(6):644-658. PubMed ID: 35482940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.
    Fleischman AG; Maxson JE; Luty SB; Agarwal A; Royer LR; Abel ML; MacManiman JD; Loriaux MM; Druker BJ; Tyner JW
    Blood; 2013 Nov; 122(22):3628-31. PubMed ID: 24081659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF3R-, ASXL1-, and SETBP1-mutated chronic neutrophilic leukemia with monoclonal gammopathy of undetermined significance in a patient who developed severe ascites due to sinusoidal neutrophilic infiltration.
    Harada N; Mukai D; Izuta Y; Shibano I; Kizawa Y; Shiragami H; Ohnishi N; Hosaka N; Mugitani A
    Pathol Int; 2024 Feb; 74(2):93-95. PubMed ID: 38050833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.